Objective. To evaluate the use of new genetic sequencing techniques for comprehensive genetic testing for hearing loss.
H earing loss is the most common sensory deficit in humans. It affects 1 in 500 newborns and more than 360 million people worldwide. In developed countries, most congenital sensorineural hearing loss (SNHL) is nonsyndromic (NSHL; not associated with any other abnormalities) and genetic. Unlike some other well-known genetic disorders caused by a single mutation (cystic fibrosis) or mutations in a single gene (Duchenne muscular dystrophy), in most cases, there are more than 80 genes and more than 1000 reported deafness-causing mutations. This extreme genetic heterogeneity makes genetic diagnosis for NSHL exceedingly difficult.
This difficulty in diagnosis is crucial to overcome, as a genetic diagnosis provides important prognostic and genetic heritability information to patients, is helpful in excluding syndromic causes of hearing loss, and can prevent other unnecessary and costly testing. As new technological advances in genetic sequencing have emerged, clinical genetic diagnosis for hearing loss has evolved from single-mutation testing to methods available today that allow comprehensive genetic testing whereby hundreds of genes are sequenced simultaneously.
From a practical standpoint, DNA sequencing requires 2 steps: enrichment of the genetic region of interest and sequencing. Genetic testing has traditionally been performed using Sanger sequencing, first developed in 1977. 1 Sanger sequencing relies on polymerase chain reaction (PCR) to isolate individual regions of the genome (typically exons), which are then subjected to sequencing. This method has an extremely high sensitivity and specificity and ushered gene sequencing in to a clinical setting. However, Sanger sequencing is hampered by low throughput and high cost. Typically, all exons of a single gene may be sequenced with this method at a cost in the clinical laboratory ranging from $1000 to $3000 per gene, with a turnaround time of about 3 months per gene. Comprehensive testing for genetically heterogeneous disorders such as NSHL is not feasible using Sanger sequencing because of cost and time constraints.
Massively parallel sequencing (MPS) was developed in the wake of the completion of the human genome project to improve throughput and decrease costs associated with DNA sequencing. MPS in general relies on targeted genomic enrichment (TGE) for simultaneous isolation of hundreds or thousands of genomic regions prior to highthroughput sequencing. A detailed description of MPS technology is outside the scope of this review but can be found elsewhere. [2] [3] [4] Sequenced genetic regions can include only exons or gene regions of interest (a targeted disease-specific gene panel) or all exons of all genes in the genome (exome sequencing).
The first studies successfully demonstrating MPS for DNA sequencing were published in 2005, 5 followed by many studies demonstrating the high throughput and accurate nature of this method for use in a variety of genetic disorders (reviewed in ref. 6) . A study published in 2010 in which the BRCA gene region was sequenced was the first to demonstrate effective diagnosis of a human genetic disease with TGE and MPS. 7 That same year, the first study showing the effectiveness of this method for diagnosis of hearing loss was published. 8 Since then, there have been a large number of studies published using this methodology for genetic diagnosis of deafness.
The goal of this review is to summarize the findings from the studies in the past 5 years using MPS as a method for comprehensive diagnosis of deafness. These studies evaluate the use of these new technologies for clinical diagnostics by examining standard clinical testing parameters using controls (including sensitivity and specificity of the method) as well as the diagnostic ability of this new type of test in patients affected by hearing loss. Our goal in this review is to provide context for clinicians who will be ordering and interpreting results from these newly developed tests.
Methods
We performed a literature search using PubMed and Google Scholar databases as of February 2015. Search criteria included several keywords used in varying combinations: deafness, hearing loss, massively parallel sequencing, and nextgeneration sequencing. Studies were excluded if the study used pooled DNA sequencing or linkage analysis, as these techniques would not be routinely used in clinical diagnostics.
Discussion

Studies Identified for Review
All 30 studies identified through the literature search are included in Table 1 . We identified 27 studies that met our criteria for inclusion and 3 that were excluded. Exclusions were due to use of pooled DNA samples in 1 case 18 and linkage analysis used in 2 cases. 11, 20 Eight of the 27 studies were case reports that primarily highlight the unique ability of comprehensive genetic testing to determine complex genetic causes of hearing loss. These 8 studies were not part of analysis for review except for 1 study, 15 which included 10 control samples in addition to the case report.
There were 7 studies that evaluated MPS with the use of controls. There were 16 studies that used MPS to evaluate patients with unknown causes of hearing loss, with 3 studies including both controls and patients with unknown causes of hearing loss ( Table 1 ).
Studies Evaluating MPS Platforms with Control Individuals
Prior to using a new technology for a clinical diagnostic test, the new test should be evaluated for sensitivity and specificity using control samples. Although Sanger sequencing has a high cost and low throughput, it has excellent specificity and sensitivity for individually targeted regions.
Any new genetic screening technology should be compared against this current gold standard.
We identified 7 studies evaluating MPS technologies for clinical diagnosis of hearing loss using 425 control individuals with previously identified causative genetic mutations and 1 study 21 that used a publically available HapMap DNA sample for formal sensitivity and specificity analysis ( Table  2) . These studies used 2 methods for genomic region isolation: targeted genomics enrichment and microdroplet PCR. Two sequencing methods were used in these 7 studies, with Illumina sequencing being the most common (7 of 8, 88%), and 1 study using Ion Torrent sequencing.
In the largest study we identified, examining 384 controls, MPS detected 159 of 174 control mutations for an overall true-positive diagnostic rate of 91.4%. 37 The 15 control mutations that were missed were located at mutation sites that were not included on the targeted enrichment platform, underscoring the importance of platform design. In the remaining 5 studies, 100% of the positive control mutations were identified in 41 samples using MPS.
Three studies included formal sensitivity and specificity analysis, including 2 studies that compared MPS to goldstandard Sanger sequencing 8,23 and 1 study in which MPS was compared with a reference human genome sequence in a publically available HapMap sample. 21 Sensitivity and specificity were both .99% in all 3 studies when evaluating a total of more than 1500 genotype calls. These data indicate that MPS is suitable for clinical genetic diagnosis of hearing loss.
Studies Evaluating Patients with Unknown Causes of Hearing Loss
We identified 16 studies in which MPS was used for genetic testing of individuals with unknown causes of hearing loss ( Table 3 ). In total, there were 603 individuals tested. The number of individuals per study varied from 6 to 125. Most (88%, 14/16) of these studies used TGE prior to sequencing, while 1 study used microdroplet PCR and 1 study used whole-exome sequencing. Illumina sequencing was used for all of the studies.
The studies varied considerably in the number of hearing loss genes targeted for sequencing from 15 to 246 genes. The current number of genes identified as harboring mutations that cause human NSHL is 84 (http:// www.hereditaryhearingloss.org). There are several reasons why the number of genes varies between studies, including (1) deafness genes are still being discovered and so the number increases over time; (2) in some cases, authors 9 Yes Baek et al 2012 10 Yes De Keleulenaer et al 2012 11 Linkage analysis Diaz-Horta et al 2012 12 Yes Eppsteiner et al 2012 13 Yes Tang et al 2012 14 Yes Wei et al 2012 15 Yes Yes Choi et al 2013 16 Yes Gao et al 2013 17 Yes Miyagawa et al 2013 18 Pooled analysis Mutai et al 2013 19 Yes Shahzad et al 2013 20 Linkage analysis Schrauwen et al 2013 21 Yes Yes Shearer et al 2013 22 Yes Sivakumaran et al 2013 23 Yes Wu et al 2013 24 Yes Yang et al. 2013 25 Yes Behar et al 2014 26 Yes Cheng et al 2014 27 Yes Gu et al 2014 28 Yes Haraksingh et al 2014 29 Yes Ji et al 2014 30 Yes Lu et al 2014 31 Yes Park et al 2014 32 Yes Qing et al 2014 33 Yes Tekin et al 2014 34 Yes Wei et al 2014 35 Yes Vona et al 2014 36 Yes Yes Nishio et al 2015 37 Yes Yes In most studies (81%, 13/16), individuals with unknown causes of hearing loss were prescreened for common deafness mutations prior to undergoing comprehensive genetic testing. This likely adequately reflects patients who may present with a request for comprehensive genetic testing for deafness after having previously been tested negative for mutations in the most common gene(s) (ie, GJB2).
Diagnostic Rate of MPS
Across the 16 studies that included 603 individuals with unknown causes of hearing loss tested with MPS, the diagnostic rate overall averaged 41% and ranged from 10% to 83% ( Table 3 ). The study with the lowest diagnostic rate, Eppsteiner et al (2012), 13 focused on adults with hearing loss and therefore may have had an ascertainment bias toward individuals with environmental or noise-induced nongenetic hearing loss. Gu et al (2014) 28 found a diagnostic rate of 13%; however, the patients were strictly prescreened and were all sporadic patients with no family history of hearing loss. Shearer et al (2010) 8 had the highest diagnostic rate but also the smallest sample size (n = 6), and so there may have been ascertainment bias. 8 Inheritance mode of hearing loss was specified in 69% of studies (11/16). Diagnostic rate was lower for individuals with autosomal recessive or sporadic inheritance (40%) when compared with the 65% diagnostic rate for individuals with autosomal dominant inheritance.
Analysis for point mutations and small deletions is routine for genetic sequencing. However, only 31% of studies (5/16) screened for large copy number variations. Copy number variations are increasingly understood to be a common cause of genetic hearing loss, accounting for between 13% and 19% of all causative mutations in 2 studies. 22, 38 Another study identified copy number variations as commonly present in hearing loss genes. 30 Others have gone so far as to advocate copy number variation analysis as a requirement for all patients undergoing genetic testing for hearing loss due to the large carrier frequency of copy number variations in the STRC gene region. 39 
Case Reports and Exome Sequencing
We also identified 8 reports that detailed cases in which comprehensive genetic testing was essential for diagnosis or highlighted the unique features of MPS ( Table 1) . Five of these reports used whole-exome sequencing (WES). This is a method of TGE whereby every exon of every gene in the human genome is isolated and enriched prior to sequencing. WES has the advantage of casting a broader net for diagnosis but comes with an increased cost of reagents and analysis. In addition, incidentally identified variants in genes not involved in hearing loss will be uncovered.
One study identified a syndromic form of hearing loss (Usher syndrome) in a patient with apparent NSHL using a deafness specific panel. 15 Two of the case reports used comprehensive genetic testing for diagnosis of families with deafness and found both nonsyndromic and syndromic forms of hearing loss segregating simultaneously. 26, 31 Two studies identified families with 3 forms of hearing loss segregating simultaneously. 31, 33 And 1 study identified a possibly life-threatening disorder, long QT syndrome caused by a mutation in KCNQ1, with exome sequencing, in a patient with what appeared to be NSHL. 34 These cases underscore the versatility of comprehensive genetic diagnosis for complex familial cases and the role of WES for complicated pedigrees.
Implications for Practice
Since the first use of MPS for genetic diagnosis of hearing loss 5 years ago, there have been 28 other studies published using this new methodology. In total, 7 studies evaluated 427 control patients to assess this methodology as a clinical diagnostic test, including formal sensitivity and specificity analysis in 3 studies. There were 16 studies evaluating the effectiveness of MPS technologies for diagnosis of NSHL in 603 individuals with unknown causes of hearing loss.
The data from the 20 studies reviewed here indicate that comprehensive genetic diagnosis using MPS is suitable for clinical use. It provides a better overall diagnostic rate on varying ethnicities (41%) than single gene testing, which must be tailored to the phenotype and population being studied and for single gene testing. For example, mutations in the gene GJB2 are the cause of between 15% and 40% of autosomal recessive NSHL in Caucasian individuals, 40 but mutations in this same gene very rarely cause genetic hearing loss in other populations. 41 This issue led to heated debate over the appropriate sequentially ordered single-gene test for a specific population and type of hearing loss. 42 Comprehensive deafness-specific testing has allowed clinical testing to move beyond that debate.
There are 4 comprehensive genetic tests for hearing loss currently available in the United States ( Table 4) . Costs have decreased such that now the cost for comprehensive genetic testing approach or are at the same level as singlegene testing. Comprehensive genetic testing has quickly become the standard of care for genetic diagnosis of sensorineural hearing loss.
This review also sheds light on several current issues regarding clinical comprehensive genetic testing for deafness that have yet to be resolved. A clinician ordering one of these tests should be aware of these controversies. First, the number and type of genes included in the platform can vary considerably. As shown in this review, there can be considerable variation in the number of genes included on a ''comprehensive'' test, ranging in our review from 34 to 246 different genes ( Table 3 ) and from 23 to 129 in currently available clinical genetic tests ( Table 4 ). As previously described, the genes included on the platform vary based on whether only NSHL genes are included, whether syndromic deafness genes are included (and which syndromes), and whether genes that are predicted to cause deafness in humans (either via animal studies or other analysis) are included.
It may seem that more is always more, but when performing genetic testing, incidental findings are of considerable concern. 43,44 Patients may not wish to know carrier status for specific diseases or risk alleles associated with diseases unrelated to the condition for which they obtained the test. Using a more targeted test reduces the risk of incidental findings. However, the benefit of including syndromic genes is that this may provide diagnoses in patients for whom a mutation in one of these genes is not suspected. For example, in 1 case report, a patient with presumed NSHL was diagnosed with long QT syndrome, which can potentially be fatal. 34 There have been several reports of Usher syndrome diagnosis in patients with apparent NSHL. 15, 22 This ability to provide a diagnosis must be weighed against incidental genetic findings. Like all incidental findings in medicine, genetic findings lead to an increase burden of referrals and other testing that the patient may not have wished for. Thus, while exome sequencing is available, it carries an increased chance of incidental findings, as well as increased cost and increased difficulty with analysis. One study comparing a disease-focused panel versus exome sequencing for inherited eye diseases found improved accuracy and performance of the disease-specific panel, a finding that also applies to panels for hearing loss. 45 For these reasons, disease-focused genetic tests have become the standard when evaluating hearing loss. 6 As illustrated by the case reports presented, exome sequencing may be valuable for more complex indications and when a deafness-specific panel has failed to determine a cause.
Finally, when considering a comprehensive genetic test, the type of mutations evaluated must be considered. All platforms include analysis of point mutations and small deletions, but large insertions or deletions are crucial for any comprehensive genetic test as these genetic alterations have been shown to be responsible for 13 or 19% of all deafness in 2 studies. 22, 46 Other groups have also advocated copy number variation analysis in all cases. 30, 39 MPS has now become well established as a clinical diagnostic tool for deafness and other genetic disorders and has become a ''cornerstone'' of clinical genetic testing. 6 The American College of Medical Genetics has developed laboratory standards for diagnostic laboratories to adhere to when performing diagnostic MPS tests, and clinicians should ensure that these standards are used by the laboratory performing the test they have ordered. 47 And as final evidence that MPS testing is now integral to effective diagnosis of deafness, the newest guideline from the American College of Medical Genetics for the evaluation of NSHL includes MPS testing as part of the standard algorithm for diagnosis. 48 Comprehensive genetic testing using MPS should now form the standard of care for genetic evaluation of patients with hearing loss. Diagnostic rates will continue to improve as new causes of hearing loss are discovered. As comprehensive hearing loss panels become more widely used, more patients will be able to obtain a genetic diagnosis, which will provide prognostic and heritability information to patients. Having a genetic diagnosis may also guide decisions on cochlear implantation 13, 32 and is the first step in designing tailor-made genetic therapies. 49 
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